Clinical examination has revealed an elevated expression of Bcl-2 anti-apoptosis family proteins in malignant glioma [3,4,5], implying a crucial role of apoptosis inactivation in glioma drug resistance, poor prognosis, and recurrence. Here, BCL2 is linked to central nervous system cancer.